CD38 plays critical role in multiple myeloma progression
A mouse model confirmed the aggressive nature of CD38 expression in multiple myeloma (MM), which induces widespread metastasis, extensive bone degradation, renal involvement,
2025 AACR Annual Meeting
2025 AACR Annual Meeting
Off-the-shelf CAR NK-cell therapy shows promise for relapsed or refractory AML
A study presented at the American Association for Cancer Research Annual Meeting 2025 found that the investigational chimeric antigen receptor (CAR) therapy SENTI-202
Meeting News
Meetings / Conferences
2025 AACR Annual Meeting
AACR honors Larry Saltzman with 2025 Distinguished Public Service Award
The American Association for Cancer Research (AACR) has named Larry Saltzman, MD, a recipient of the 2025 Distinguished Public Service Award for his
Multiple Myeloma
News
Early intervention with daratumumab for smoldering myeloma may delay disease progression
Researchers observed delayed progression to multiple myeloma (MM) in patients with smoldering MM (SMM) who were treated with single-agent daratumumab.
Lymphoma
EMA approves OT-C001 trial in DLBCL
The European Medicines Agency (EMA) has approved an Investigational Medicinal Product Dossier (IMPD) for OT-C001.
Leukemia
Acute Myeloid Leukemia
News
Triplet ‘effective’ in relapsed or refractory AML
A phase 2 study found that cladribine, idarubicin, and cytarabine (CLIA) was “effective” in treating relapsed or refractory acute myeloid leukemia (AML).
Multiple Myeloma
News
Real-world data support efficacy of IsaPd triplet in relapsed/refractory myeloma
A real-world, multicenter study supported findings from the pivotal ICARIA-MM clinical trial, showing that isatuximab, pomalidomide, and dexamethasone (IsaPd) was an efficacious and tolerable
Society Updates
Registration open for 13th Annual Meeting of the Society of Hematologic Oncology
The Society of Hematologic Oncology (SOHO) has opened registration for its annual meeting; register before June 8, 2025, for early-bird rates. Event dates: September
Lymphoma
News
Early-phase trial shows promise for refractory CD30-positive lymphoma
A CD30/CD16A bispecific antibody, AFM13, “showed encouraging preliminary safety and efficacy
Lymphoma
Aggressive B-Cell Lymphomas
ELM-1 cohort study assesses odronextamab after CAR-T therapy for DLBCL
Odronextamab monotherapy resulted in a 48.3% overall response rate in patients with diffuse large B-cell lymphoma (DLBCL) who had progressed after chimeric antigen